2Hoffman R, Benz Jr ET, Shattil SJ, et al. Hematology basic principles and practice[M]. 3rd ed (北京影印版).北京:科学出版社,2001:383-387,2350-2366,2414-2421.
3Bergamaschi G, Markopoulos K, Albertini, et al. Anemia of chronic disease and defective erythropoietin production in patients with celiac disease [J]. Hematologica, 2008, 93 ( 12 ) : 1785-1791.
4McHutchison JG, Manns MP, Longo DE. Definition and management of anemia in patients infected with hepatitis C virus [J]. Liver Int,2006,26(4) :389-398.
5Younossi ZM, Nader F H,Bai C, et al. A phase Ⅱ dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatits C treatment [J]. Viral,2008,15(5) :370-378.
1United States Renal Data System(USRDS) Annual Report,2000.
2Keller C. Dtsch Med Wochenschr,2000 ,125:250-254.
3Ritz Acta Diabetol,2002, 39 (suppl1): S53-S58.
4日本《医学论坛报》，2003，36：29．
5Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis, 2000,35 (6 Suppl 2):S1-140.
6Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant,2004,19: 1-47.
7Wilmink H, Stores ESG, Gerritsten W, et al. Effect of folic acid on post- prandial endothelial dysfunction. Arterioscler Thromb Vasc Biol,2000,20:185-8.
8Zhou XJ, VaziriND. Defective calcium signalling in uraemic platelets and its amelioration with long - term erythropoietin therapy. Nephrol Dial Transplant,2002,17(6):992 -7.
